Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Hemangioma 3Prostatic Neoplasms 2Uterine Cervical Neoplasms 1Melanoma 1Hemangioma, Cavernous, Central Nervous System 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Cisplatin 18pembrolizumab 12Paclitaxel 9Carboplatin 9Radiotherapy 5Gemcitabine 4Fluorodeoxyglucose F18 4Colposcopy 4Brachytherapy 4fludarabine 3durvalumab 3Surveys and Questionnaires 3Radiation 3Flow Cytometry 3Cyclophosphamide 3Biopsy 3Bevacizumab 3toripalimab 2fludarabine phosphate 2atezolizumab 2aldesleukin 2adavosertib 2Zoledronic Acid 2Topotecan 2Nivolumab 2Neoadjuvant Therapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Interleukin-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uterine Cervical Neoplasms × Propranolol × Clear all
NCT01902966 2021-10-12

Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

M.D. Anderson Cancer Center

Phase NA Terminated
6 enrolled 8 charts
Gynecologic

Anxiety Disorders, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡